Core Viewpoint - The company forecasts a revenue of 6.013 billion yuan for H1 2025, representing an 18% year-over-year increase, while net profit is expected to decline by 21% to 35% year-over-year, primarily due to increased non-cash share payments and rising operational costs associated with brand expansion and legal services [1] Group 1: Business Performance - The company’s revenue growth in H1 2025 is attributed to strengthened enforcement and regulatory policies in the U.S. and parts of Europe, leading to good growth in both its proprietary brand and ToB businesses [1] - The adjusted net profit for H1 2025 is projected to be between 688 million and 787 million yuan, reflecting a year-over-year change of -9% to +4% [1] Group 2: Regulatory Environment - The U.S. FDA and state governments have intensified enforcement against non-compliant electronic vapor products, which has positively impacted the sales of compliant products [2] - In Europe, regulations on disposable e-cigarettes have tightened, with bans in the UK and New Zealand taking effect, which is expected to shift consumer demand towards compliant products [2] Group 3: New Business Development - The Glo Hilo product, launched in Japan, has shown improved performance compared to its Serbian counterpart, with enhanced heating efficiency and a wider variety of flavor options [3] - The product is set to be rolled out nationwide in Japan, which is anticipated to benefit the company as a product innovator and supply chain partner [3] Group 4: Financial Forecast and Valuation - The company maintains its profit forecast, expecting net profits of 1.323 billion, 2.140 billion, and 2.762 billion yuan for 2025-2027, with corresponding EPS of 0.21, 0.35, and 0.45 yuan [3] - A target price of 25.00 HKD is set, reflecting a valuation premium due to high competitive barriers in the HNB new business and the steady recovery of the vapor main business [3]

Core Viewpoint - The company is expected to see a significant improvement in its performance due to the favorable regulatory environment for vaping products and the growth of its heated non-combustible tobacco (HNB) business [1][2]. Financial Performance - For the first half of 2025, the company anticipates revenue of 6.013 billion yuan, representing an 18% year-on-year increase [1]. - The projected net profit for 2025H1 is between 443 million and 541 million yuan, indicating a year-on-year decline of 21% to 35%, with a midpoint decrease of 28% [1]. - Adjusted net profit, excluding stock incentive expenses, is expected to be between 688 million and 787 million yuan, reflecting a year-on-year change of -9% to +4%, with a midpoint of -2.5% [1][2]. Business Analysis - The company’s vaping business is benefiting from increased enforcement against illegal products in the U.S., with the FDA and customs seizing nearly 34 million USD worth of illegal e-cigarettes [1]. - The U.S. Senate has approved a 200 million USD budget for the FDA to combat illegal vaping products, indicating a positive regulatory trend for the compliant market [1]. - In Europe, the UK has banned disposable e-cigarettes, leading to a potential increase in sales of refillable products, which the company is well-positioned to capitalize on [1]. - The HNB product Glo hilo is currently in pilot sales in Serbia and Sendai, Japan, and is expected to contribute positively in the future [1]. Profitability Outlook - The company’s profitability is expected to improve due to a higher proportion of high-margin vaping products and the ongoing development of the HNB business [2]. - The adjusted profit margin is anticipated to show improvement, driven by the enhanced product mix in the vaping segment [2]. - The company is positioned uniquely in the market as the only listed entity deeply integrated into the supply chain of major overseas tobacco groups, which provides a competitive edge [2]. Earnings Forecast - The company projects earnings per share (EPS) of 0.21, 0.42, and 0.58 yuan for the years 2025 to 2027, with corresponding price-to-earnings (PE) ratios of 94, 48, and 34 times [2].

Investment Rating - The report does not provide a specific investment rating for the company [1] Core Views - The company is expected to achieve a revenue of 60.13 billion yuan in the first half of 2025, representing an 18.3% year-on-year increase. However, the total comprehensive income is projected to be between 4.51 billion and 5.51 billion yuan, indicating a decline of 23.9% to 37.8% year-on-year, with a median estimate of 5.01 billion yuan, which is a 30.8% decrease [1] - The company anticipates maintaining double-digit revenue growth in Q2 2025, although profits are under pressure due to increased share-based payment expenses of 176 million yuan and a rise in sales and management expense ratios [1] - The company is actively responding to market changes, with expectations for stable growth despite regulatory pressures on traditional disposable products. The company is focusing on expanding its compliance product offerings and enhancing its self-owned brand overseas [2] - The HILO product is performing well, with an accelerated expansion in the Japanese market, which is expected to contribute positively to the company's HNB growth [2] - Profit forecasts for the company indicate net profits of 12.1 billion, 20.3 billion, and 30.0 billion yuan for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 99.4X, 59.3X, and 40.3X [2] Financial Summary - The total revenue for 2024 is projected at 11.799 billion yuan, with a growth rate of 6%. For 2025, the revenue is expected to be 12.011 billion yuan, reflecting a 2% growth. The net profit attributable to the parent company is forecasted to be 1.303 billion yuan in 2024, decreasing to 1.213 billion yuan in 2025, before rising to 2.034 billion yuan in 2026 and 2.995 billion yuan in 2027 [4][6] - The company's operating income is expected to grow from 11.799 billion yuan in 2024 to 17.063 billion yuan in 2027, with a compound annual growth rate of approximately 22.57% [4][6] - The company's cash flow from operating activities is projected to be 1.753 billion yuan in 2024, decreasing to 942 million yuan in 2025, and then increasing to 3.084 billion yuan by 2027 [7]

Group 1: Market Overview - The Hang Seng Index rose by 0.07%, gaining 17 points to close at 24,534 points, while the Hang Seng Tech Index increased by 0.29% [1] - The early trading volume in the Hong Kong stock market reached HKD 128.7 billion [1] Group 2: Innovative Drug Sector - The innovative drug sector is experiencing a resurgence, driven by favorable policies and expectations from BD, with institutions noting that the current valuations remain attractive [1] - The Hang Seng Biotechnology Index surged by 4.41% [1] Group 3: Notable Stock Performances - Lepu Biotech-B (02157) saw a significant increase of over 13% [1] - Kangfang Biotech (09926) rose by 10.16% [1] - Kangruoya-B (02162) increased by 12.4% [1] - Sangfor Biopharma (01530) gained 8.94% [1] - Fudan Zhangjiang (01349) surged by 23.9% due to progress in ADC platform development [2] - King’s Ray Biotech (01548) increased by over 6%, with CARVYKTI sales in Q2 growing approximately 136% year-on-year [3] - Ascentage Pharma-B (06855) rose by 4.87%, with recent fundraising exceeding HKD 1.49 billion and the approval of a new drug application [4] - Terns Pharmaceuticals-B (02137) increased by over 6% after granting exclusive rights for a new drug in Greater China [5] - BeiGene (06160) rose by 8.39% after the acceptance of a listing application for a dual-specificity antibody [6] - Damai Entertainment (01060) increased by 7.27%, becoming the official channel for Scottish Super League matches [7] - Bilibili-W (09626) rose by over 4%, with growth in gaming and advertising business leading to a target price upgrade by Bank of America [8] - Fenbi (02469) surged by over 14% following the release of its AI test preparation program, with expectations of improved profit margins due to increased penetration [9] - Smoore International (06969) fell by 1%, with expected net profit decline of up to 35% in the first half of the year due to rising expenses [10]

Group 1: Market Performance - Bilibili-W (09626) rose over 4% due to growth in gaming and advertising, with Bank of America raising the target price to HKD 211 [1] - Innovation drugs continue to attract funding, with companies like 3SBio (01530) up over 8%, CanSino Biologics (09926) up over 12%, and others reaching historical highs [1] - DaMai Entertainment (01060) increased over 5% as it became the official channel for Scottish Super League matches, indicating growth in sports ticketing [1] Group 2: Industry Developments - The National Healthcare Security Administration of China initiated the 11th batch of centralized drug procurement, focusing on mature "old drugs" and excluding innovative drugs from the procurement [1] - In the first half of this year, the total amount of License out for Chinese innovative drugs approached USD 66 billion, surpassing the total BD transaction amount for 2024, indicating sustained interest from multinational corporations [1] Group 3: Company-Specific News - Meitu (01357) rose over 5% due to significant progress in overseas lifestyle and productivity scene expansion, including a strategic partnership with Alibaba [2] - Tengsheng Bo Pharmaceutical-B (02137) increased over 7% after granting exclusive rights for a new drug in Greater China to Health元 Group [2] - Smoore International (06969) fell over 2% as it expects a profit decline of up to 35% in the first half of the year due to increased expenses [2] Group 4: Notable Stock Movements - Blueport Interactive (08267) surged over 40% after establishing the LK Crypto division to accelerate Web3 and RWA layout [2] - Gilead Sciences-B (01672) saw an early morning increase of over 11% as clinical research for ASC47 in treating obesity was completed [2] - MicroPort Medical (0853.HK) rose over 6% as it considers a non-binding proposal to restructure its CRM business [3]

Macro Insights - The US June CPI shows partial transmission of tariffs, with core CPI rising 0.23% month-on-month, slightly below the expected 0.3% [2] - Core CPI year-on-year increased by 0.1 percentage points to 2.9%, aligning with expectations [2] - The overall CPI month-on-month rose from 0.08% in May to 0.29%, with a year-on-year increase of 0.3 percentage points to 2.7%, slightly above the expected 2.6% [2] Fixed Income - The bond market remains in a warm supply-demand environment despite short-term disturbances, with credit demand still increasing [3] - The central bank continues to support technology innovation bonds, with expectations of a slight compression in the yield spread of related ETFs [3] - Short-term disturbances have led to a focus on medium to short-duration investments, particularly in high-quality city investment bonds and industries with high growth potential [3] Electronics Industry - ASML's Q2 2025 performance met prior guidance, with new orders significantly increasing, although logic customer orders saw a notable decline [5] - ASML projects Q3 2025 revenue between €7.4 billion and €7.9 billion, with a year-on-year growth of 2.5% and a quarter-on-quarter decline of 0.5% [5] - The semiconductor industry continues to see strong demand driven by AI, with expectations for domestic advanced process and storage expansion [5] Basic Chemicals - Glyphosate prices have increased by 9% year-on-year to ¥25,901 per ton, driven by seasonal demand in South America and production cuts [6] - The domestic and international planting areas are expected to rise, leading to a potential bottom reversal for glyphosate prices, benefiting leading domestic companies [6] Energy and Power Equipment - Gansu province has introduced a capacity pricing policy for power generation, which is expected to enhance the profitability of energy storage [7] - The policy sets a capacity price of ¥330 per kilowatt per year for coal power units and new energy storage, with a two-year execution period [7] - The domestic energy storage market is anticipated to see increased demand in the short, medium, and long term due to clearer profitability models [7] Construction and Engineering - The recent central urban work conference indicates a shift from rapid urbanization to stable development, focusing on quality improvement of existing urban infrastructure [8] - The construction materials industry is expected to face demand changes and supply transformation challenges as urban renewal becomes a priority [8] - Key areas of focus include pipeline renovation, architectural coatings, and infrastructure projects with quick asset recovery [8] Transportation - Airlines have maintained a high passenger load factor of 84.6%, with a year-on-year increase of 1.7 percentage points [9] - Despite limited capacity growth during the summer travel season, ticket prices have shown weakness, indicating potential challenges in revenue management [9] - The airline sector is recommended for investment, particularly in China National Aviation and Huaxia Airlines, due to expected profitability improvements [9] ETF Market - The domestic ETF market expanded by nearly ¥580 billion in the first half of 2025, reaching a total scale of ¥4.3 trillion [11] - Bond ETFs and Hong Kong stock ETFs have become major attractors of capital, with significant growth in several thematic ETFs [11] - The performance of trading-type ETFs is closely linked to market conditions, while configuration-type ETFs can achieve steady growth through continuous marketing [11]

Summary of Smoore International and the E-Cigarette Industry Update Company and Industry Overview - **Company**: Smoore International - **Industry**: E-Cigarette and Vapor Products Key Points and Arguments 1. **Revenue Performance**: Smoore International reported an 18% year-on-year increase in revenue for the first half of 2025, with both ODM business and free brand business showing strong growth, particularly among small clients [2][5] 2. **U.S. Market Recovery**: The enforcement of regulations against non-compliant disposable e-cigarettes in the U.S. is expected to clear the market of non-compliant products, creating a better environment for compliant products and aiding Smoore's business recovery [3][7] 3. **European Market Changes**: The implementation of a ban on disposable e-cigarettes in Europe starting June 1, 2025, is anticipated to increase the market share of compliant products, which is favorable for Smoore in the long term [4][7] 4. **Profit Decline Factors**: Smoore's profit decreased by 21% to 35% in the first half of 2025, primarily due to increased equity incentive costs and legal-related expenses, with equity incentive costs expected to rise by over 300 million yuan for the year [5][12] 5. **New Product Trials in Japan**: The new product Hilo, developed in collaboration with British American Tobacco, has shown optimistic trial results in Sendai, Japan, with a high user satisfaction rate and a significant conversion rate from traditional smokers [6][7] 6. **Future Growth Trends**: The HNB (Heat-Not-Burn) market is expected to grow, with favorable conditions in the U.S. and Europe, and successful product trials in Japan indicating a positive outlook for Smoore's future [7][10] 7. **Impact of Tariffs on Indonesian Factory**: The tariff issues related to the Indonesian factory are expected to have a limited impact on overall performance due to high product markup and low unit prices, as the products are considered addictive consumer goods [8][12] 8. **Sales Performance in Japan**: The overall sales situation in Japan is optimistic, with expectations of meeting annual performance guidance despite 2025 not being a high-profit year [9][10] 9. **Traditional E-Cigarette Market Trends**: The traditional e-cigarette market in the U.S. and Europe is showing marginal improvement, indicating a positive trend in both policy and operational aspects [10][12] 10. **THC and Medical Aesthetics Growth**: The THC vaporization products are stabilizing, and related fields such as medical aesthetics are showing promising growth prospects, potentially providing new growth opportunities for Smoore [11][12] Additional Important Insights - **Stock Volatility and Investment Value**: Despite lower profits in 2025, Smoore's long-term investment value remains significant, warranting close attention from investors [12]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company is expected to achieve strong revenue growth in 25H1, with a forecasted revenue of 60.13 billion, representing an 18% year-on-year increase, outperforming market expectations [1] - Profit is projected to decline to between 4.43 billion and 5.41 billion, a decrease of 21% to 35% year-on-year, with an average estimate of 4.92 billion, indicating a significant narrowing of the profit decline in Q2 [1][2] - The decline in profit is attributed to increased incentive costs, marketing investments, and legal service fees, with adjusted net profit expected to be between 6.88 billion and 7.87 billion, reflecting a year-on-year change of -9% to +4% [2] Revenue Insights - The company's revenue from vaping products has shown resilience due to regulatory improvements, with all products being compliant [3] - The implementation of bans on disposable e-cigarettes in various regions, including the UK and New Zealand, has led to a shift towards open and refillable e-cigarettes, benefiting the company's sales [3] Future Outlook - The recent trial sales of HNB products in Japan have received positive feedback, with expectations for significant market share growth as the product is set for nationwide launch on September 1 [4] - The pricing strategy for Glo Hilo in Japan has been adjusted to enhance supply chain value distribution, indicating a strong competitive position [4] Financial Forecast and Valuation - The company is projected to achieve revenues of 131.61 billion, 155.90 billion, and 186.33 billion from 2025 to 2027, with year-on-year growth rates of 11.55%, 18.45%, and 19.52% respectively [5] - Net profit is expected to reach 13.11 billion, 20.40 billion, and 27.63 billion during the same period, with growth rates of 0.57%, 55.68%, and 35.40% respectively [5] - The current market capitalization corresponds to a PE ratio of 90.72X, 58.28X, and 43.04X for the years 2025 to 2027 [5]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 25.00, up from the previous target of HKD 16.25 [6][4]. Core Insights - The company is expected to see a revenue increase of 18% year-on-year for the first half of 2025, with projected revenue of HKD 60.13 billion. However, net profit is forecasted to decline by 21% to 35% year-on-year, primarily due to increased non-cash share payments and rising operational costs associated with expanding its proprietary brand business [1][4]. - The regulatory environment in the US and Europe is tightening, which is anticipated to drive demand for compliant products, positively impacting the company's core vaporization business [2][4]. - The new HNB product, Glo Hilo, has shown promising performance in the Japanese market, indicating significant growth potential for the company as it expands its product offerings [3][4]. Summary by Sections Revenue and Profit Forecast - The company forecasts a net profit of HKD 13.23 billion, HKD 21.40 billion, and HKD 27.62 billion for the years 2025 to 2027, respectively, with corresponding EPS of HKD 0.21, HKD 0.35, and HKD 0.45 [4][10]. Market and Regulatory Environment - The report highlights that the enforcement of regulations by the FDA in the US and similar measures in Europe are expected to restore sales of compliant vapor products, benefiting the company's market position [2][4]. Product Development and Innovation - The Glo Hilo product, launched in Japan, features enhanced heating efficiency and a variety of flavor options, which are expected to validate the product's market potential and drive future growth [3][4]. Valuation Metrics - The report assigns a PE ratio of 65 for 2026, reflecting the company's strong growth prospects and competitive advantages in the HNB market, leading to a target price increase [4][10].

Group 1 - The Hang Seng Index rose by 0.28%, gaining 68 points to close at 24,658 points, while the Hang Seng Tech Index increased by 0.61% [1] - The Hong Kong stock market saw a trading volume of HKD 157.9 billion in the morning session [1] - The National Healthcare Security Administration of China added innovative commercial insurance drugs to the list for 2025, supporting new drugs with high clinical value but payment bottlenecks, leading to a rise in the Hang Seng Biotechnology Index [1] Group 2 - Livzon Pharmaceutical (01513) surged by 12.69% as the Phase II clinical trial for its cardiovascular innovative drug H001 capsule completed patient enrollment [2] - InnoCare Pharma (02577) increased by 6.41%, planning to significantly enhance its 8-inch gallium nitride wafer production capacity over the next five years [2] - China Heartland Fertilizer (01866) rose by 3.83% following reports of a meeting held by relevant authorities to ensure the supply and stabilize prices of potash fertilizer [2] Group 3 - Chongqing Machinery and Electric (02722) saw a significant increase of over 17% due to catalysts in the domestic AIDC market, with Chongqing Cummins being a supplier for engines [2] Group 4 - Jifang Zhitu Holdings (09636) rose by 10.18% after announcing a proposed share placement to raise approximately HKD 746 million for developing on-chain financial resources [3] Group 5 - Smoore International (06969) fell by 3.55%, expecting a year-on-year decline of approximately 21% to 35% in half-year profits [4] - Kanglong Chemical (03759) issued a profit warning, dropping by 5.24%, with an expected year-on-year decline of 36% to 39% in net profit attributable to shareholders for the first half [5]